Effects of a SGLT2 inhibitor on glucose metabolism and body composition in patients with type 2 diabetes

Effects of a SGLT2 inhibitor on glucose metabolism and body composition in patients with type 2 diabetes - Effects of a SGLT2 inhibitor on glucose metabolism and body composition in patients with type 2 diabetes

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000015402

Enrollment

Registered

2014-11-01

Start date

2014-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Patients with type 2 diabetes mellitus 2.HbA1c 7.0-10.0% 3.Patients who have received anti-diabetics without any change over at least 3 months 4.The change in body weight is 2 kg or less and that of HbA1c is 0.5% or less over at least 3 months 5.Patients who provided written informed consent

Exclusion criteria

Exclusion criteria: 1.Serious infection 2.Serious liver and/or kidney disease 3.End stage renal disease with undergoing hemodialysis or peritoneal dialysis

Design outcomes

Primary

Measure	Time frame
HbA1c, fasting plasma glucose, insulin, body weight, fat mass, lean body mass, food consumption	—

Secondary

Measure	Time frame
serum osmolality, urine osmolality, blood urea nitrogen, serum creatinine, LDL cholesterol, HDL cholesterol, triglyceride, free fatty acid, GOT, GPT, glucagon, GLP-1	—

Countries

Japan

Contacts

Public ContactToshio Iwakura

Kobe City Medical Center General Hospital Department of Diabetes and Endocrinology

iwakura@kcho.jp078-302-4321

Outcome results